Trial of the Efficacy of Intravenous Immunoglobulin for Treating Women With Unexplained Secondary Recurrent Miscarriage

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00722475
Recruitment Status : Completed
First Posted : July 25, 2008
Last Update Posted : November 6, 2014
The Ministry of Science, Technology and Innovation, Denmark
Information provided by (Responsible Party):
Ole B Christiansen, Rigshospitalet, Denmark

Brief Summary:
The investigators want to test whether infusions of intravenous immunoglobulin - a blood product known to modify immune responses - in early pregnancy will increase the chance of a subsequent live birth in women with three or more miscarriages after a birth and a total of at least four miscarriages. This will be done in a trial where 82 patients will be randomly allocated to infusions with intravenous immunoglobulin or placebo during pregnancy.

Condition or disease Intervention/treatment Phase
Secondary Recurrent Miscarriage Drug: Intravenous immunoglobulin Drug: Human albumin Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 82 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-controlled, Double-blind Trial of Intravenous Immunoglobulin for Women With Unexplained Secondary Recurrent Miscarriage
Study Start Date : August 2008
Actual Primary Completion Date : May 2014
Actual Study Completion Date : May 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Miscarriage

Arm Intervention/treatment
Experimental: IvIg
Repeated infusions of intravenous immunoglobulin in early pregnancy
Drug: Intravenous immunoglobulin
Intravenous infusions, 25-35 g each time, 4th to 15th gestational week
Other Name: Intravenous immunoglobulin Privigen CSL Behring 100mg/ml

Placebo Comparator: placebo
infusion of human albumin CSL Behring 5%
Drug: Human albumin
Repeated infusions of Human Albumin 5%, 250-350 ml between 4th and 15th gestational week
Other Name: Human Albumin 5% CSL Behring

Primary Outcome Measures :
  1. The difference in the subsequent livebirth rate among patients with secondary recurrent miscarriage who, during the trial, receive intravenous immunoglobulin or placebo, respectively, without any exclusions (ITT analysis) [ Time Frame: August 2008 to June 2011 ]

Secondary Outcome Measures :
  1. The difference in the subsequent livebirth rate among women with secondary recurrent miscarriage who receive intravenous immunoglobulin or placebo, respectively, after relevant and predefined exclusions (PP analysis). [ Time Frame: August 2008 to June 2011 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 4 or more miscarriages before the end of gestational week 14 in patients with secondary recurrent miscarriages.
  • At least three of these must be consecutive after the previous birth
  • At least two of the miscarriages with the present partner.

Exclusion Criteria:

  • Age below 18 or above 41 years at conception
  • Significant uterine anomalies detected by hysterosalpingography, hysteroscopy or hydrosonography.
  • Significant chromosomal aberrations in the couple
  • Menstrual cycle < 23 or > 35 days
  • Presence of lupus anticoagulant or IgG anticardiolipin concentration >= 40 GPL ku/l or plasma homocystein >= 25 microg./l by repeated measurements at 8 weeks intervals
  • Tests positive for HIV or tests indicating carriage of hepatitis B or C
  • IgA deficiency
  • Allergy to albumin, IvIg or one of the substances added to preserve the drugs.
  • Presence of chronic disease, which necessitate permanent treatment with e.g. corticosteroids , non-steroidal antiinflammatory drugs, anticoagulation, simvastatin or imurel from the start of pregnancy.
  • Less than 2 of the previous pregnancy losses documented by ultrasound or uterine curettage.
  • Present pregnancy a result of donor insemination or egg donation.
  • Planned administration of gestagens or estrogens from the beginning of pregnancy.
  • 3 or more previous IVF/ICSI/FER attempts resulting in chemical pregnancy/miscarriage.
  • Previous participation in the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00722475

Fertility Clinic 4071, Rigshospitalet
Copenhagen, Denmark, DK-2100
Sponsors and Collaborators
Rigshospitalet, Denmark
The Ministry of Science, Technology and Innovation, Denmark
Principal Investigator: Ole B. Christiansen, MD, D.M.Sc. Rigshospitalet, Denmark

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Ole B Christiansen, consultant, Rigshospitalet, Denmark Identifier: NCT00722475     History of Changes
Other Study ID Numbers: IvIg for recurrent miscarriage
EudraCT nr. 2008-001589-94
First Posted: July 25, 2008    Key Record Dates
Last Update Posted: November 6, 2014
Last Verified: November 2014

Keywords provided by Ole B Christiansen, Rigshospitalet, Denmark:
recurrent miscarriage
intravenous immunoglobulin

Additional relevant MeSH terms:
Neoplasm Metastasis
Abortion, Spontaneous
Abortion, Habitual
Neoplastic Processes
Pathologic Processes
Pregnancy Complications
Immunoglobulins, Intravenous
Rho(D) Immune Globulin
Immunologic Factors
Physiological Effects of Drugs